Other News To Note
Thursday, August 30, 2012
Noven Pharmaceuticals Inc., of Miami, a subsidiary of Hisamitsu Pharmaceutical Co. Inc., said it submitted a new drug application seeking to market low-dose mesylate salt of paroxetine for the treatment of vasomotor symptoms associated with menopause.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.